Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 1059-1063

  Ruiz Carrascoso, Guillermo ^a   Casas, Inmaculada ^a   Pozo, Francisco ^a   González Vincent, Marta ^b   Pérez Breña, Pilar ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CORTICOSTEROID DERIVATIVE; FLUDARABINE; HEMAGGLUTININ; MELPHALAN; OSELTAMIVIR; PROTEIN M2; TACROLIMUS; VIRUS SIALIDASE;

ANTIGEN DETECTION; ARTICLE; B LYMPHOCYTE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; NEUROTOXICITY; NOSE SMEAR; NUCLEOTIDE SEQUENCE; OXYGEN THERAPY; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; RHINORRHEA; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; THORAX RADIOGRAPHY; THROAT CULTURE; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS SHEDDING;

AMANTADINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRAL MATRIX PROTEINS;

EID: 78651106234     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1657     Document Type: Article

References (16)

1. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-1561. (Pubitemid 44901897)
2. Rocha E, Cox NJ, Black RA, Harmon MW, Harrison CJ, Kendal AP. Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J Virol 1991; 65:2340-2350.
3. Centers for Disease Control and Prevention. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:893-896.
4. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:1435-1441.
5. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-764.
6. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348:867-868. (Pubitemid 36245772)
7. Coiras MT, Aguilar JC, Garcia ML, Casas I, Perez-Brena P. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. J Med Virol 2004; 72:484-495.
8. Lopez-Huertas MR, Casas I, Acosta-Herrera B, Garcia ML, Coiras MT, Perez-Brena P. Two RT-PCR based assays to detect human metapneumovirus in nasopharyngeal aspirates. J Virol Methods 2005; 129:1-7.
9. Ruiz-Carrascoso G, Casas I, Pozo F, Pérez-González C, Reina J, Pérez-Breña P. Development and implementation of influenza A virus subtyping and detection of genotypic resistance to neuraminidase inhibitors. J Med Virol 2010; 82:843-853.
10. Holsinger LJ, Shaughnessy MA, Micko A, Pinto LH, Lamb RA. Analysis of the posttranslational modifications of the influenza virus M2 protein. J Virol 1995; 69:1219-1225.
11. Matrosovich M, Gao P, Kawaoka Y. Molecular mechanisms of serum resistance of human influenza H3N2 virus and their involvement in virus adaptation in a new host. J Virol 1998; 72:6373-6380. (Pubitemid 28323948)
12. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002; 34:E23-E25.
13. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103:199-203.
14. Saito R, Sakai T, Sato I, et al. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J Clin Microbiol 2003; 41:2164-2165.
15. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-257. (Pubitemid 47047464)
16. Grantham ML, Wu WH, Lalime EN, Lorenzo ME, Klein SL, Pekosz A. Palmitoylation of the influenza A virus M2 protein is not required for virus replication in vitro but contributes to virus virulence. J Virol 2009; 83:8655-8661.